Weiss Multi-Strategy Advisers’s BridgeBio Pharma BBIO Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-46,067	Closed	-$1.86M	–	49
2023 Q4	$1.86M	Buy	+46,067	New	+$1.38M	0.04%	377
2023 Q3	–	Sell	-59,889	Closed	-$1.03M	–	553
2023 Q2	$1.03M	Buy	59,889 +22,177	+59%	+$334K	0.02%	537
2023 Q1	$625K	Buy	+37,712	New	+$440K	0.01%	540

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Weiss Multi-Strategy Advisers's BBIO Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 46,067 shares — an estimated $1.86M sold.

Weiss Multi-Strategy Advisers first reported a position in BBIO in Q1 2023 and held it in 3 quarters. The position peaked at $1.86M in Q4 2023. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 46,067 BridgeBio Pharma shares in Q1 2024, an estimated $1.86M.
Weiss Multi-Strategy Advisers first reported a position in BridgeBio Pharma in Q1 2023 and held it in 3 quarters.
Weiss Multi-Strategy Advisers's BridgeBio Pharma position peaked at $1.86M in Q4 2023.
244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.